NASDAQ$VKTX
Viking Therapeutics Inc · Q4 2021 earnings
Q4 2021 earnings · · Investor relations
Briefing
Reported financial results for the fourth quarter and year ended December 31, 2021, and provided an update on its clinical pipeline and other corporate developments.
Viking Therapeutics reported a net loss of $12.4 million, or $0.16 per share, for the fourth quarter ended December 31, 2021. The company's research and development expenses were $9.8 million, and general and administrative expenses were $2.7 million. The company ended the quarter with $202.1 million in cash, cash equivalents and short-term investments.
- Enrollment continued in the Phase 2b VOYAGE trial evaluating VK2809 for the treatment of NASH and fibrosis.
- A Phase 1b trial evaluating VK0214 in X-ALD patients was placed on hold pending completion of a preclinical study.
- A Phase 1 trial of the novel dual incretin receptor agonist VK2735 is underway.
- The company ended the fourth quarter with $202.1 million in cash, cash equivalents and short-term investments.
Headline financials
Revenue & EPS history
Viking Therapeutics · Revenue · Quarterly
$0
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2021
+1.6%
Avg return
Earnings day
+4.3%
Avg return
5 days after
+10.3%
Avg return
30 days after
48%
21 / 44 earnings
Positive
+25.5%
Q2 2024
Best reaction
-12.1%
Q1 2020
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -1.8% | -0.1% | +4.4% | |
| Q4 2025 | +6.8% | +6.7% | +24.8% | |
| Q3 2025 | +8.1% | +11.2% | +9.0% | |
| Q1 2025 | -0.5% | +8.3% | +4.6% | |
| Q4 2024 | -6.1% | -10.6% | -13.1% | |
| Q3 2024 | +18.0% | +20.1% | -15.2% | |
| Q2 2024 | +25.5% | +18.8% | +25.4% | |
| Q1 2024 | +6.1% | +16.2% | -3.4% | |
| Q4 2023 | +17.4% | +28.9% | +191.7% | |
| Q3 2023 | -9.2% | -10.0% | +15.3% | |
| Q2 2023 | -5.4% | +0.1% | -6.0% | |
| Q1 2023 | -1.4% | +11.3% | +7.2% | |
| Q4 2022 | +7.2% | +6.7% | +3.9% | |
| Q3 2022 | -1.5% | +0.2% | -2.0% | |
| Q2 2022 | -2.1% | -12.0% | +2.1% | |
| Q1 2022 | +5.7% | +10.5% | +1.7% | |
| Q4 2021 | +12.8% | +4.5% | -11.4% | |
| Q3 2021 | +5.5% | +3.0% | -22.9% | |
| Q2 2021 | +6.5% | +6.5% | +9.5% | |
| Q1 2021 | +0.5% | +0.3% | -15.9% | |
| Q4 2020 | -11.1% | -15.2% | -25.7% | |
| Q3 2020 | +0.2% | +0.4% | +19.9% | |
| Q2 2020 | +14.4% | +10.8% | +3.6% | |
| Q1 2020 | -12.1% | +7.9% | +15.3% | |
| Q4 2019 | -6.4% | -4.4% | -28.9% | |
| Q3 2019 | +12.0% | +19.8% | +6.0% | |
| Q2 2019 | -5.9% | -6.0% | -9.6% | |
| Q1 2019 | +7.9% | +6.2% | -1.9% | |
| Q4 2018 | -3.3% | +6.5% | +17.2% | |
| Q3 2018 | -4.4% | -14.6% | -29.9% | |
| Q2 2018 | -0.2% | +3.0% | +8.6% | |
| Q1 2018 | +9.8% | +10.0% | +133.4% | |
| Q4 2017 | -7.1% | -0.2% | -27.2% | |
| Q3 2017 | -5.2% | +16.9% | +76.6% | |
| Q2 2017 | +6.3% | +8.4% | +21.1% | |
| Q1 2017 | -5.1% | -9.4% | -8.7% | |
| Q4 2016 | -7.8% | -7.8% | +6.2% | |
| Q3 2016 | +10.0% | +18.0% | +12.0% | |
| Q2 2016 | -3.8% | -3.8% | +2.3% | |
| Q1 2016 | +5.9% | — | — | |
| Q4 2015 | -10.7% | — | — | |
| Q3 2015 | -9.9% | — | — | |
| Q2 2015 | +5.7% | — | — | |
| Q1 2015 | -2.3% | — | — | |
| Q4 2014 | — | — | — | |
| Q3 2014 | — | — | — | |
| Q2 2014 | — | — | — | |
| Q1 2014 | — | — | — | |
| Q4 2013 | — | — | — | |
| Q3 2013 | — | — | — | |
| Q2 2013 | — | — | — | |
| Q1 2013 | — | — | — | |
| Q4 2012 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro